

Product Information

SILu™Prot CCL2, C-C motif chemokine 2, human recombinant, expressed in HEK cells
SIL MS Protein Standard, ¹³C- and ¹⁵N-labeled

Catalog Number **MSST0035**

Storage Temperature **–20 °C**

Synonyms: HC11, Monocyte chemoattractant protein 1, Monocyte chemotactic and activating factor (MCAF), Monocyte chemotactic protein 1(MCP-1), Monocyte secretory protein JE, Small-inducible cytokine A2

Product Description

SILu™Prot CCL2 is a recombinant, stable isotope-labeled human CCL2 which incorporates [¹³C₆, ¹⁵N₄]-Arginine and [¹³C₆, ¹⁵N₂]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of CCL2 in mass spectrometry. SILu™Prot CCL2 is a homodimer consisting of 96 amino acids (including C-terminal polyhistidine and FLAG® tags), with a calculated molecular mass of 11.2 kDa.

CCL2, the most thoroughly characterized CC chemokine, is a monocyte-specific chemoattractant that was demonstrated to attract T lymphocytes and NK cells, but not neutrophils.¹ Enhanced expression of CCL2 was demonstrated in a variety of pathologic conditions, associated with inflammation and mononuclear cell infiltration.¹ Extensive experimental evidence suggests CCL2 is highly expressed in atherosclerotic plaques.² In a recent study, CCL2 was shown to have value as a biomarker for risk stratification in both the initial and the chronic phases after an acute coronary syndrome (ACS). In contrast to CRP, CCL2 levels may be an indicator of long-term cardiovascular risk rather than a marker of acute prognosis.¹ In urine, CCL2 levels were directly associated to Systemic Lupus Erythematosus disease activity, making it a non-invasive biomarker (avoiding blood sampling or tissue biopsies).³

Each vial contains 10–13 µg of SILu™Prot CCL2 standard, lyophilized from a solution of phosphate buffered saline. Vial content was determined by the Bradford method using BSA as a calibrator. The correction factor from the Bradford method to Amino Acid Analysis is 60% for this protein.

Identity: Confirmed by peptide mapping

Purity: ≥95% (SDS-PAGE)

Heavy amino acid incorporation efficiency: ≥98% (MS)

UniProt: P13500

Sequence Information

The C-terminal polyhistidine and FLAG tags are italicized.

QPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPK
EAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPK
TDYKDDDDKGHHHHHHHHGGGQ

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile ultrapure water to a final concentration of 100 µg/mL.

Storage/Stability

Store the lyophilized product at –20 °C. The product is stable for at least 2 years as supplied. After reconstitution, it is recommended to store the protein in working aliquots at –20 °C.

References

1. Gonzalez-Quesada, C., and Frangogiannis, N.G., Monocyte Chemoattractant Protein (MCP-1)/CCL2 as a biomarker in Acute Coronary Syndromes. *Curr. Atheroscler. Rep.*, **11**, 131-138 (2009).
2. Nelken, N.A. et al., Monocyte chemoattractant protein-1 in human atheromatous plaques. *J. Clin. Invest.*, **88**, 1121-1127 (1991).
3. Barbado, J. et al., MCP-1 in urine as biomarker of disease activity in Systemic Lupus Erythematosus, *Cytokine*, **60**, 583-586 (2012).

FLAG is a registered trademark and SILu is a trademark of Sigma-Aldrich Co. LLC.

Legal Information

Sold under license from DuPont, U.S. Patent No. 7,396,688.

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.

JK,KR,MAM 10/16-1